New Clinical Data on Day 3 Embryo Transfers Using Eeva™ Technology Presented at the Association of Clinical Embryologists 2014 Conference

- Similar Pregnancy Rates Seen with Day 3 Transfer Incorporating Eeva Results in Embryo Selection Versus Day 5 Transfer Utilizing Only Morphological Assessment  

- New Eeva Enhancements Also Introduced at ACE Conference

SHEFFIELD, England and MENLO PARK, California, Jan. 6, 2014 /PRNewswire/ -- Results of a clinical study utilizing the Eeva™ Technology by Auxogyn, that showed similar pregnancy rates among patients when embryos were transferred on Day 3 utilizing Eeva information versus Day 5 blastocyst transfers relying on morphology alone, were presented today at the Association of Clinical Embryologists (ACE) 2014 Conference by Chris Adam, Laboratory Manager of the Glasgow Centre for Reproductive Medicine (GCRM Ltd).

"We are very pleased with the data being presented today at ACE," said Professor Fleming, Scientific Director of GCRM Ltd. "This further demonstrates how IVF clinicians and their patients can benefit from the early information that Eeva provides to assist in embryo selection."

Lissa Goldenstein, President and CEO of Auxogyn stated, "This data, combined with the launch of our most recently enhanced version of Eeva, are further evidence of how Auxogyn is advancing reproductive health and providing clinical evidence that people can trust when making important IVF treatment decisions." 

The comparative study included a total of 328 patients between the ages of 25 and 42, of which 161 elected to incorporate the Eeva results selecting embryo(s) for a day 3 transfer.  Concurrently, 167 patients were enrolled for comparison and had a standard day 5 blastocyst transfer based on morphological assessment. Both groups had comparable patient clinical characteristics, number of eggs, number of embryos and number of embryos transferred. 

Key findings presented at the conference indicate that the adjunct usage of Eeva with cleavage stage embryo transfer achieved implantation rates that were similar to a standard day 5 transfer (clinical pregnancy rates 42% in both groups).

"We are encouraged by these data which have had a clear impact on our clinic," stated Professor Fleming. "We now have evidence that incorporating Eeva results in the selection of embryos to transfer at Day 3 cleavage stage achieves results that are comparable with Day 5 blastocyst transfers. We believe it is a viable alternative to Day 5 blastocyst transfer, which could reduce the potential risks that may be associated with extended culture and further simplify laboratory procedures".

Auxogyn is also announcing today the launch of Eeva 2.2, which offers several new features to further assist clinicians in assessing embryo development potential and selecting the best embryo(s) to transfer. 

About Auxogyn
Auxogyn is a leader in reproductive health that provides novel scientific and clinically validated solutions to IVF clinicians and their patients by translating scientific discoveries in early embryo development into clinical tools.  The Company's flagship product, the Eeva™ Test, delivers objective information regarding embryo development that IVF clinicians and patients can use to make important treatment decisions.  Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech.  For more information visit auxogyn.com and follow us on Twitter @Auxogyn.

About the Eeva™ Test
The Eeva Test provides IVF clinicians with information about the embryo's development potential.  Eeva proprietary software automatically analyzes embryo development against scientifically validated cell-division parameters conceived by researchers at Stanford University in the US.  With results from the Eeva Test, IVF teams will have morphological assessment and objective information to aid their embryo selection decisions.  The Eeva Test was evaluated in a prospective, multi-center, 160-patient prospective multi-center trial with ~1,800 embryos.  Results of this study were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting and published by Conaghan et al in Fertility and Sterility, May 2013.

The Eeva Test is currently CE Marked and available for use in the EU and authorized by Health Canada for sale in Canada.  The FDA submission is pending and Eeva is not available for sale in the United States.  For a full list of clinics in the EU offering the Eeva Test please visit www.eevaivf.com or follow us on Twitter @EevaIVF.